MDPI and ACS Style
Nagane, M.; Ichimura, K.; Onuki, R.; Narushima, D.; Honda-Kitahara, M.; Satomi, K.; Tomiyama, A.; Arai, Y.; Shibata, T.; Narita, Y.;
et al. Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study. Cancers 2022, 14, 5522.
https://doi.org/10.3390/cancers14225522
AMA Style
Nagane M, Ichimura K, Onuki R, Narushima D, Honda-Kitahara M, Satomi K, Tomiyama A, Arai Y, Shibata T, Narita Y,
et al. Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study. Cancers. 2022; 14(22):5522.
https://doi.org/10.3390/cancers14225522
Chicago/Turabian Style
Nagane, Motoo, Koichi Ichimura, Ritsuko Onuki, Daichi Narushima, Mai Honda-Kitahara, Kaishi Satomi, Arata Tomiyama, Yasuhito Arai, Tatsuhiro Shibata, Yoshitaka Narita,
and et al. 2022. "Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study" Cancers 14, no. 22: 5522.
https://doi.org/10.3390/cancers14225522